Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 136 AL 150

Mitochondrial dysfunction: A potential target for Alzheimer's disease intervention and treatment

Ke J, Tian Q, Xu Q, Fu Z, Fu Q.

Drug Discov Today. 2021 Aug;26(8):1991-2002. doi: 10.1016/j.drudis.2021.04.025. Epub 2021 May 5.

Narrative review: recent advances in doll therapy for Alzheimer's disease

Cai X, Zhou L, Han P, Deng X, Zhu H, Fang F, Zhang Z.

Ann Palliat Med. 2021 Apr;10(4):4878-4881. doi: 10.21037/apm-21-853.

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease

Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, Booler H, Bravo J, Brendza R, Brunstein F, Chan R, Chandra P, Couch JA, Datwani A, Demeule B, DiCara D, Erickson R, Ernst JA, Foreman O, He D, Hötzel I, Keeley M, Kwok MCM, Lafrance-Vanasse J, Lin H, Lu Y, Luk W, Manser P, Muhs A, Ngu H, Pfeifer A, Pihlgren M, Rao GK, Scearce-Levie K, Schauer SP, Smith WB, Solanoy H, Teng E, Wildsmith KR, Bumbaca Yadav D, Ying Y, Fuji RN, Kerchner GA.

Sci Transl Med. 2021 May 12;13(593):eabb2639. doi: 10.1126/scitranslmed.abb2639.

Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)

Ferreira JPS, Albuquerque HMT, Cardoso SM, Silva AMS, Silva VLM.

Eur J Med Chem. 2021 Oct 5;221:113492. doi: 10.1016/j.ejmech.2021.113492. Epub 2021 Apr 24.

Role of γ-Secretase Inhibitors for the Treatment of Diverse Disease Conditions through Inhibition of Notch Signaling Pathway

Mondal A, Bose S, Banerjee S, Pal D.

Curr Drug Targets. 2021;22(15):1799-1807. doi: 10.2174/1389450122666210515161312.

Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives

Fasae KD, Abolaji AO, Faloye TR, Odunsi AY, Oyetayo BO, Enya JI, Rotimi JA, Akinyemi RO, Whitworth AJ, Aschner M.

J Trace Elem Med Biol. 2021 Sep;67:126779. doi: 10.1016/j.jtemb.2021.126779. Epub 2021 May 15.

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease

Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P; REVERSE-SD Study Investigators.

Alzheimers Res Ther. 2021 May 27;13(1):106. doi: 10.1186/s13195-021-00843-2.

Adiponectin: a potential target for obesity-associated Alzheimer's disease

Samant NP, Gupta GL.

Metab Brain Dis. 2021 Oct;36(7):1565-1572. doi: 10.1007/s11011-021-00756-x. Epub 2021 May 28.

Comprehensive Management of Daily Living Activities, behavioral and Psychological Symptoms, and Cognitive Function in Patients with Alzheimer's Disease: A Chinese Consensus on the Comprehensive Management of Alzheimer's Disease

Jia J, Xu J, Liu J, Wang Y, Wang Y, Cao Y, Guo Q, Qu Q, Wei C, Wei W, Zhang J, Yu E.

Neurosci Bull. 2021 Jul;37(7):1025-1038. doi: 10.1007/s12264-021-00701-z. Epub 2021 May 29.

Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease

Richard E, den Brok MGHE, van Gool WA.

Alzheimers Dement. 2021 Jun;17(6):1051-1055. doi: 10.1002/alz.12379. Epub 2021 May 31.

Virtual Reality-Based Cognitive Stimulation on People with Mild to Moderate Dementia due to Alzheimer's Disease: A Pilot Randomized Controlled Trial

Oliveira J, Gamito P, Souto T, Conde R, Ferreira M, Corotnean T, Fernandes A, Silva H, Neto T.

Int J Environ Res Public Health. 2021 May 16;18(10):5290. doi: 10.3390/ijerph18105290.

Neuroprotective Natural Products for Alzheimer's Disease

Chen X, Drew J, Berney W, Lei W.

Cells. 2021 May 25;10(6):1309. doi: 10.3390/cells10061309.

[Donepezil Reduces Amyloid Precursor Protein Endocytosis by Resulting from Increase in the Expression of Sorting Nexin Protein 33]

Takada-Takatori Y.

Yakugaku Zasshi. 2021;141(6):851-856. doi: 10.1248/yakushi.20-00251-6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias